Evommune, Inc.
EVMN$769M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPALO ALTO45 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
EVMN News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
EVO101
Atopic Dermatitis Eczema
Oral EVO756
Chronic Inducible Urticaria
EVO756
Chronic Spontaneous Urticaria
EVO301
Atopic Dermatitis (AD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EVO101 | Phase 2 | Atopic Dermatitis Eczema | - | - |
Oral EVO756 | Phase 2 | Chronic Inducible Urticaria | - | - |
EVO756 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
EVO301 | Phase 2 | Atopic Dermatitis (AD) | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply